Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Haemoglobin-based red cell substitutes: current status

J E Ogden1, S L Mac Donald

  • 1Propharma Consultants, Nottingham, UK.

Vox Sanguinis
|January 1, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pharmaceutical services in the Department of Veterans Affairs.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·1997
Same author

Expression of rat neuronal nitric oxide synthase in Saccharomyces cerevisiae.

Journal of biotechnology·1996
Same author

Comparison of Department of Veterans Affairs pharmacy services in 1992 and 1994 with strategic-planning goals.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·1996
Same author

High level synthesis and secretion of human urokinase using a late gene promoter of the Autographa californica nuclear polyhedrosis virus.

Journal of biotechnology·1995
Same author

Inhibition of nitric oxide synthase--potential for a novel class of therapeutic agent?

Trends in biotechnology·1995
Same author

The development of hemoglobin solutions as red cell substitutes.

International anesthesiology clinics·1995
Same journal

Barriers and enablers to non-remunerated plasma donation: A meta-synthesis of the qualitative literature using the theoretical domains framework.

Vox sanguinis·2026
Same journal

Haemolytic disease of the foetus and newborn due to anti-M: A systematic review.

Vox sanguinis·2026
Same journal

In vitro evaluation of apheresis platelet and plasma products collected and stored in non-DEHP disposable sets.

Vox sanguinis·2026
Same journal

Survey of national and regional rare donor programmes regarding Immunoglobulin A deficiency.

Vox sanguinis·2026
Same journal

Fibrinogen recovery in cryoprecipitate prepared from thawed plasma stored for 5 days post-thaw.

Vox sanguinis·2026
Same journal

Abstracts of the 39th International Congress of the ISBT, Kuala Lumpur, Malaysia, 20-24 June 2026.

Vox sanguinis·2026
See all related articles

Chemically modified hemoglobin solutions offer potential blood transfusion alternatives with advantages like universal compatibility. Ongoing trials are assessing their safety and efficacy for treating hemorrhagic shock and in surgery.

Area of Science:

  • Biomedical Engineering
  • Hematology
  • Resuscitation Medicine

Background:

  • Chemically modified hemoglobin solutions are being developed as alternatives to donor blood transfusions.
  • These products offer theoretical benefits including enhanced oxygen delivery, extended shelf-life, universal compatibility, and viral safety.

Purpose of the Study:

  • To evaluate the potential of chemically modified hemoglobin solutions as blood transfusion alternatives.
  • To address safety concerns such as renal toxicity, coagulopathy, and vasoactivity associated with these products.

Main Methods:

  • Phase I safety trials have been completed in human subjects.
  • Phase II safety and efficacy trials are planned for the near future.

Main Results:

Related Experiment Videos

  • Three chemically modified hemoglobin products have successfully completed Phase I safety trials.
  • Further clinical trials are necessary to establish efficacy and comprehensive safety profiles.

Conclusions:

  • Chemically modified hemoglobin solutions show promise as alternatives to blood transfusion, particularly for hemorrhagic shock resuscitation and perioperative hemodilution.
  • Continued research and clinical trials are essential to validate their safety and efficacy in patient care.